Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

44.61 1.28 −2.79%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a

Alkermes plc (ALKS) Gross margin

Alert me on Gross margin

Alkermes plc's gross margin over the twelve months to 30 September 2026 was 82.9%, down 3.8 percentage points from fiscal 2025 (86.7%). Over the past ten years it has ranged from 77.9% (fiscal 2015) to 86.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 53.5% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 86.7% 2.44
FY2024 84.3% (0.54)
FY2023 84.8% 4.40
FY2022 80.4% (2.80)
FY2021 83.2% 0.36
FY2020 82.8% (1.76)
FY2019 84.6% 0.71
FY2018 83.9% 1.01
FY2017 82.9% 0.59
FY2016 82.3% 4.40

Quarterly newest first

Period Gross margin Change (points)
Sep 2026 80.4% 0.16
Jun 2026 80.2% (4.11)
Mar 2026 84.3% (3.65)
Dec 2025 88.0% 1.07
43 more quarters

Against its own ten years

Low 77.9% High 86.7%
Ten-year median 83.2%
Current reading's percentile 35

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on ALKS